The EMEA committee for Orphan Medicinal Products has adopted a positive opinion on orphan medicinal product designation for Isotechnika's ISA247, a treatment for chronic, non-infectious uveitis.
The EMEA committee for Orphan Medicinal Products has adopted a positive opinion on orphan medicinal product designation for Isotechnika's ISA247, a treatment for chronic, non-infectious uveitis.
Lux Biosciences, which has an exclusive worldwide license for ISA247 in ophthalmic indications, began enrolling subjects into three pivotal clinical trials earlier this year. Collectively known as LUMINATE, the trials represent the most comprehensive clinical programme ever undertaken in the field of uveitis.
The US FDA has already granted fast track designation to the drug.
